Lymphoma Brands

Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.

Roche's anti-CD20 chimeric monoclonal antibody (rituximab) co-developed by Genentech and IDEC Pharmaceuticals, FDA approved November 26, 1997, as the first monoclonal antibody approved for cancer treatment, now facing biosimilar competition from Truxima, Ruxience, and Riabni.